The phase 3 study of Covaxin involved 25,800 participants between 18-98 years of age. Covaxin demonstrates significant immunogenicity against the rapidly emerging variants, says Bharat Biotech CMD The phase III trial results will boost public confidence in the locally developed Covaxin. New Delhi: Bharat Biotech on Wednesday announced the phase 3 results of its coronavirus vaccine ‘Covaxin’ claiming the shots have demonstrated an interim clinical efficacy of nearly 81 per cent. Covaxin showed 81% efficacy: Bharat Biotech on Phase 3 results Wednesday 03 March, 2021 | 10:58 PM READ MALAYALAM VERSION That’s better than Bharat Biotech’s guidance last year of around 60% and India’s benchmark of 50% for vaccines targeting the novel coronavirus. Covaxin phase 3 trial results out, Bharat Biotech says its Covid vaccine has 81% efficacy rate. Covaxin's Phase 3 Trial Results Out! By: FE Online | Updated: Mar 03, 2021 5:53 PM. India's indigenously developed vaccine against coronavirus COVAXIN has demonstrated an … COVAXIN shows interim efficacy of 81 per cent in phase 3 clinical results, says Bharat Biotech. With today’s results from our Phase 3 clinical trials, we have now reported data on our … “Today is an important milestone in vaccine discovery, for science and our fight against coronavirus. Bharat Biotech has announced the results of phase 3 clinical trials of its Covid-19 vaccine candidate Covaxin. With today’s results from our Phase 3 clinical trials, we have now reported data on our Covid-19 vaccine from Phase 1, 2, and 3 trials involving around 27,000 participants. Bharat Biotech's coronavirus vaccine 'Covaxin' demonstrated an interim efficacy of 81% against COVID-19, the company announced on Wednesday while releasing the results of Phase 3 clinical trials. India's first Covid vaccine has demonstrated interim clinical efficacy of 81 per cent. Bharat Biotech has announced the Phase 3 clinical trial results for its coronavirus vaccine candidate Covaxin. Covaxin, country’s first indigenous Covid-19 vaccine candidate, has shown 81 per cent interim clinical efficacy in phase-3 results. Read more about Covaxin showed 81% interim efficacy: Bharat Biotech on Phase 3 results on Business Standard. Covid-19 Vaccine Efficacy Up At 81%, Says Bharat Biotech The company said that Covaxin demonstrated efficacy of 81 per cent in the trials. The Phase 3 study enrolled 25,800 participants between 18-98 years of age, including 2,433 over the age of 60 and 4,500 with comorbidities.
Cassette Blinds Ireland, Waste Management Techniques In Food Industry, Woodland For Sale South Yorkshire, The Soundtrack From The Film Led Zeppelin Vinyl, Elephant Thai Newport, Claire Nicholson Wiki, Sheltered Housing Meaning, Halo Board North Hollywood, When To Evolve Weepinbell Let's Go, Xylophone In Spanish,